Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 5/5/2025 and 6/24/2026 was considered by the examiner.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-11 and 13-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Grahek et al. (US 2016/0346207; of record).
Grahek describes anticancer compositions according to the following tablet compositions:
PNG
media_image1.png
221
401
media_image1.png
Greyscale
and
PNG
media_image2.png
213
408
media_image2.png
Greyscale
. Examples 5 and 6 contain enzalutamide and sodium lauryl sulfate (an anionic surfactant) or PEG 6000 (a nonionic surfactant polymer) in an amount of about 15wt% of the tablet dosage, wherein the final form has a total weight of less than 1000 mg wherein the dosage comprises 20% enzalutamide adsorbate in an amount of 200 mg (40 mg enzalutamide net) (see instant claims 1, 10, 11, 13, 14 and 16-18).
Enzalutamide is taught as being entirely crystalline (see Reference Examples 3 and 4) and thus the composition would contain enzalutamide having a degree of crystallinity of at least 60% (see instant claims 2 and 3).
Reference Examples 4 and 5 produce nanoparticles having a median size of 0.37 microns (i.e. 370 nm) and 0.12 microns (i.e. 120 nm), respectively (see [0170]) (see instant claims 1 and 4-6). Regarding the instant requirement that the z-average diameter be determined with ISO22412:2008 particle size analysis, this is an intended use limitation and does not limit the composition itself but instead provides a means by which the particle size can be determined. See MPEP 2111.02(II).
Grahek teaches enzalutamide is present in the composition in an amount of at least 15% and that the composition may comprise various polymers such as polyvinyl pyrrolidone, HPMC and polyvinyl alcohol (see [0047]; see instant claim 15). Although Grahek fails to teach the amount of drug and excipient in an overlapping amount, such amounts would reasonably be modified so as to fit ones desires and if the result was a composition that the excipients in the nanoparticles are not more than 75wt% (or 70wt%) especially given that Grahek provides a baseline for which the base composition may be modified from (e.g. ‘;at least’). Accordingly, manipulation of the prior arts teaching to achieve that claimed would have been an obvious modification of the prior art. See MPEP 2144.06.
Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary.
Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Grahek et al. (US 2016/0346207; of record) as applied to claims 1-11 and 13-18 above, and further in view of Liversidge et al. (US 5399363; of record).
Grahek fails to teach the composition as comprising a surfactant selected from sodium dodecyl sulfate, tocopherol polyethylene glycol 1000 succinate and poloxamer.
Liversidge is directed to nanoparticulate anticancer compositions. The composition is to comprise a surface active agent such as sodium dodecyl sulfate and sodium lauryl sulfate (see claim 15). It would have been obvious to include sodium dodecyl sulfate given that it was a known obvious variant of the sodium lauryl sulfate described by Grahek. The selection of a known material based on its intended use is evidence of obviousness.
Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-18 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1, 5, 8, 13, 17-19, 21, 23, 29, 33, 35, 39, 64, 66, 68, 69, 72, 74, and 76 of copending Application No. 19/148303 (reference application).
Although the claims at issue are not identical, they are not patentably distinct from each other because the references claims are directed to a composition comprising nanoparticles of crystalline enzalutamide and one or more polymers wherein the nanoparticles have a size of at most 800 nm and at least 10 nm wherein the weight ratio of enzalutamide to the polymer is from 5:1 to 1:5. The present claims are similarly directed to crystalline enzalutamide nanoparticles having a size of not more than 700 nm and comprising various polymers such as PVP/VA. All other limitations are essentially identical in that the compositions contain the same active, have similar particle sizes, similar surfactants/polymers, etc.. Thus, the claims of the copending application are not patentably distinct over the instantly claimed subject matter.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/KYLE A PURDY/Primary Examiner, Art Unit 1611